Eli Lilly announces ‘positive’ top-line results for Taltz

Eli Lilly announces ‘positive’ top-line results for Taltz

Eli Lilly announces 'positive' top-line results for Taltz. Stockwinners.com
Eli Lilly announces ‘positive’ top-line results for Taltz

Eli Lilly (LLY) announced that Taltz met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis, or AS, also known as radiographic axial spondyloarthritis, or axSpA.

The trial included a placebo arm and an active control arm, or adalimumab, for comparison with placebo, and studied patients who had never received a biologic disease-modifying anti-rheumatic drug, or bDMARD. Taltz demonstrated a statistically significant improvement in the signs and symptoms of AS, as measured by the proportion of patients who achieved Assessment of Spondyloarthritis International Society 40, or ASAS40, response at 16 weeks, when compared to placebo.

COAST-V is the first registration trial to use ASAS40 as the primary endpoint, compared to the standard endpoint of ASAS20. AS is one type of spondyloarthritis that affects the pelvic joints and spine, and can be characterized by chronic inflammatory back pain, stiffness and impaired function and mobility.

Of those affected by AS, approximately 80 percent will experience symptoms before age 30. In COAST-V, the incidence of treatment-emergent adverse events was similar with Taltz compared with placebo.

The most common adverse events observed were consistent with the Phase 3 studies of ixekizumab for the treatment of moderate-to-severe plaque psoriasis and active psoriatic arthritis.

Lilly plans to submit detailed data from COAST-V for disclosure at scientific meetings and in peer-reviewed journals later this year.

The company plans to submit for regulatory approvals pending additional data from the ongoing Taltz development program later this year.

Ankylosing spondylitis , or AS, is a form of arthritis that primarily affects the spine, although other joints can become involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort.

In more advanced cases this inflammation can lead to ankylosis — new bone formation in the spine — causing sections of the spine to fuse in a fixed, immobile position.

LLY closed at $76.25.


To read timely stories similar to this, along with money making trade ideas, sign up for a membership to Stockwinners

This article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Leave a Reply

Your email address will not be published. Required fields are marked *